Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
No investor of THAR Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 32 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
People named by THAR Pharmaceuticals Inc.
Name
Role
Named in
Brian K. Moyer
Vice President, Corporate Development & Finance
Apr 2016
Ira K. Kalfus
Chief Medical Officer of Issuer
Apr 2016
Jason K. Bablak
Vice President, Regulatory Affairs
Apr 2016
Mazen K. Hanna
Chief Scientific Officer
Apr 2016
Raymond K. Houck
President, Chief Executive Officer and Director of Issuer
Apr 2016
Brian Moyer
Executive officer
Nov 2013
Jason Bablak
Executive officer
Nov 2013
Mazen Hanna
Executive officer
Nov 2013
Raymond Houck
Executive officer
Nov 2013
Lalit K. Chordia
Director
Apr 2016
Philip K. Sussman
Director
Apr 2016
Raymond K. Houck
President, Chief Executive Officer and Director of Issuer